| Literature DB >> 28054247 |
Valery M Dembitsky1, Tatyana A Gloriozova2, Vladimir V Poroikov2.
Abstract
This paper describes research on naturalEntities:
Keywords: Alkaloids; Azo metabolites; Bacteria; Fungi; Plant; SAR; Sponges
Year: 2017 PMID: 28054247 PMCID: PMC5315673 DOI: 10.1007/s13659-016-0117-3
Source DB: PubMed Journal: Nat Prod Bioprospect ISSN: 2192-2209
Confirmed and new biological activities of azo compounds (1–10) derived from actinomycetes
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Antibiotic antineoplastic | Antineoplastic (0.985) | Phobic disorders treatment (0.819) |
|
| Not studied | – | Antineoplastic (0.880) |
|
| Not studied | – | Phobic disorders treatment (0.907) |
|
| Antibiotic | – | Hepatic disorders treatment (0.872) |
|
| Antibiotic | Antibacterial (0.507) | Hepatic disorders treatment (0.819) |
|
| Antibiotic | Antibacterial (0.527) | Hepatic disorders treatment (0.765) |
|
| Antibiotic antifungal | Antifungal (0.640) | Hepatic disorders treatment (0.778) |
|
| Antibiotic antifungal | – | Phobic disorders treatment (0.860) |
|
| Antifungal | Antifungal (0.658) | Hepatic disorders treatment (0.793) |
|
| Antifungal | Antifungal (0.632) | Hepatic disorders treatment (0.819) |
aOnly activities with Pa > 0.5 are shown
Fig. 1Biological active azo compounds derived from actinomycetes
Confirmed and new biological activities of azo compounds (11–21) derived from actinomycetes
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Antibiotic anti-mycobacterial | Antibacterial (0.489) | Hepatic disorders treatment (0.733) |
|
| Antibiotic antifungal cytotoxic | Antifungal (0.646) | Hepatic disorders treatment (0.763) |
|
| Antibiotic antifungal cytotoxic | Antifungal (0.639) | Vasodilator (0.722) |
|
| Antibiotic cytotoxic | Antineoplastic (0.549) | Phobic disorders treatment (0.769) |
|
| Antibiotic cytotoxic | Antineoplastic (0.599) | Hepatic disorders treatment (0.604) |
|
| Antibiotic antibacterial | – | Phobic disorders treatment (0.834) |
|
| Antibiotic antibacterial | – | Phobic disorders treatment (0.888) |
|
| Antibiotic antibacterial | – | Phobic disorders treatment (0.837) |
|
| Nematocide | – | Hepatic disorders treatment (0.849) |
|
| Nematocide | – | Hepatic disorders treatment (0.849) |
|
| Antibiotic antineoplastic | Antineoplastic (0.672) | Antiviral (arbovirus) (0.557) |
aOnly activities with Pa > 0.5 are shown
Confirmed and new biological activities of azo compounds (22–39) derived from actinomycetes
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Antibiotic antifungal | – | Antineoplastic (0.845) |
|
| Antibiotic | – | Antineoplastic (0.781) |
|
| Antibacterial antineoplastic | Antineoplastic (0.923) | Antifungal (0.633) |
|
| Antibacterial antineoplastic | Antineoplastic (0.927) | Spasmolytic, urinary (0.687) |
|
| Antibiotic antifungal | Antifungal (0.640) | Hepatic disorders treatment (0.778) |
|
| Antibiotic antifungal | Antifungal (0.658) | Hepatic disorders treatment (0.793) |
|
| Antineoplastic antibiotic cytotoxic ornithine decarboxylase inhibitor | Anti-Helicobacter pylori (0.995) | Kidney function stimulant (0.636) |
|
| Antineoplastic antibiotic | – | Anti-Helicobacter pylori (0.994) |
|
| Microtubule inhibitor | – | Anti-Helicobacter pylori (0.893) |
|
| Microtubule inhibitor | – | Anti-Helicobacter pylori (0.915) |
|
| Not studied | – | Antiseborrheic (0.793) |
|
| Nematocide | – | Antiseborrheic (0.793) |
|
| Nematocide | – | Anti-Helicobacter pylori (0.939) |
|
| Not studied | – | Antiinflammatory (0.714) |
|
| Not studied | – | Anti-Helicobacter pylori (0.932) |
|
| Nematocide cytotoxic | – | Anti-Helicobacter pylori (0.932) |
|
| Not studied | – | Apoptosis agonist (0.935) |
|
| Not studied | – | Apoptosis agonist (0.920) |
aOnly activities with Pa > 0.5 are shown
Fig. 2Aromatic azo compounds derived from actinomycetes and fungal species
Confirmed and new biological activities of azo compounds (40–58) derived from actinomycetes and fungal species
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Not studied | – | Antiinflammatory (0.957) |
|
| Not studied | – | Hemostatic (0.962) |
|
| Not studied | – | Antiinflammatory (0.964) |
|
| Not studied | – | Antiinflammatory (0.953) |
|
| Not studied | – | Antiinflammatory (0.961) |
|
| Insecticide | – | Antieczematic (0.732) |
|
| Insecticide | – | Immunosuppressant (0.647) |
|
| Not studied | – | Preneoplastic (0.692) |
|
| Not studied | – | Antimutagenic (0.758) |
|
| Not studied | – | Antiseborrheic (0.874) |
|
| Not studied | – | Carminative (0.817) |
|
| Not studied | – | Antieczematic (0.843) |
|
| Not studied | – | Phobic disorders treatment (0.840) |
|
| Not studied | – | Acaricide (0.821) |
|
| Not studied | – | Alopecia treatment (0.762) |
|
| Not studied | – | Phobic disorders treatment (0.916) |
|
| Not studied | – | Phobic disorders treatment (0.700) |
|
| Not studied | – | Fibrinolytic (0.640) |
|
| Not studied | – | Mucositis treatment (0.831) |
aOnly activities with Pa > 0.5 are shown
Confirmed and new biological activities of azo compounds (59–77) derived from actinomycetes and fungal species
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Not studied | – | Mucositis treatment (0.776) |
|
| Not studied | – | Antiviral (arbovirus) |
|
| Not studied | – | Genital warts treatment (0.726) |
|
| Not studied | – | Genital warts treatment (0.726) |
|
| Not studied | – | Genital warts treatment (0.726) |
|
| Not studied | – | Mucositis treatment (0.761) |
|
| Antibiotic antineoplastic | Antineoplastic (breast cancer) (0.552) | Alopecia treatment (0.641) |
|
| Not studied | – | Antineoplastic (0.868) |
|
| Antifungal | Antifungal (0.690) | Hepatic disorders treatment (0.994) |
|
| Antifungal | Antifungal (0.662) | Hepatic disorders treatment (0.987) |
|
| Vasodilator Acyl CoA synthetase inhibitor | Vasodilator (0.881) | Antieczematic (0.830) |
|
| Acyl CoA synthetase inhibitor | Vasodilator (0.759) | Spasmolytic (0.649) |
|
| Acyl CoA synthetase inhibitor | – | Antieczematic (0.917) |
|
| Acyl CoA synthetase inhibitor | – | Vasodilator (0.881) |
|
| Antimicrobial antiviral antineoplastic | Antineoplastic (0.409) | Antiischemic, cerebral (0.752) |
|
| Antimicrobial antiviral antineoplastic | Antineoplastic (solid tumors) (0.618) | Genital warts treatment (0.656) |
|
| Antimicrobial antiviral antineoplastic | Antineoplastic (sarcoma) (0.482) | Gout treatment (0.865) |
|
| Antimicrobial antiviral antineoplastic | – | Guanyl-specific ribonuclease T1 inhibitor (0.709) |
|
| Antimicrobial antiviral antineoplastic | Antineoplastic (sarcoma) (0.469) | Anxiolytic (0.896) |
aOnly activities with Pa > 0.5 are shown
Fig. 3Miscellaneous azo compounds produced by actinomycetes and fungal species
Confirmed and new biological activities of azo compounds (78–97) derived from actinomycetes and fungal species
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Antimicrobial antiviral antineoplastic | Antineoplastic (sarcoma) (0.413) | Atherosclerosis treatment (0.924) |
|
| Cytotoxic antineoplastic | Antineoplastic (0.584) | Endothelial growth factor antagonist (0.885) |
|
| Not studied | – | Phobic disorders treatment (0.728) |
|
| Not studied | – | Antineurotic (0.694) |
|
| Not studied | – | Lysase stimulant (0.787) |
|
| Not studied | – | Lysase stimulant (0.787) |
|
| Interleukin 4 antagonist | – | Antiseborrheic (0.815) |
|
| Antibacterial | – | Antineurotic (0.806) |
|
| Not studied | – | Not predicted: MolCharge: 1 |
|
| Not studied | – | Not predicted: MolCharge: 1 |
|
| Cytotoxic | Antineoplastic (0.666) | Pterin deaminase inhibitor (0.989) |
|
| Cytotoxic antifungal | – | Antiallergic (0.765) |
|
| Antineoplastic antileukemic | Antineoplastic (0.749) | Genital warts treatment (0.936) |
|
| Antineoplastic antileukemic | Antineoplastic (0.752) | Antimetabolite (0.938) |
|
| Antibiotic | – | Antineoplastic (sarcoma) (0.730) |
|
| Not studied | – | Antineoplastic(0.768) |
|
| Antimicrobial antiviral antineoplastic | Glycopeptide-like antibiotic (0.627) | Analgesic (0.637) |
|
| Antimicrobial antiviral antineoplastic | Glycopeptide-like Antibiotic (0.714) | Analgesic (0.670) |
|
| Antimicrobial antiviral antineoplastic | Glycopeptide-like antibiotic (0.625) | Analgesic (0.601) |
|
| Antimicrobial antiviral antineoplastic | Glycopeptide-like antibiotic (0.713) | Analgesic (0.641) |
aOnly activities with Pa > 0.5 are shown
Fig. 4Biological active triazole derivatives, siderophores and octapeptides derived from actinomycetes and fungal species
Confirmed and new biological activities of azo compounds (98–117) derived from plants
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Cytotoxic | Antineoplastic (0.730) | Antiprotozoal (plasmodium) (0.641) |
|
| Immunosuppressant | – | β-1,3-galactosyl-O-glycosyl-glycoprotein β-1,6-N-acetylglucosaminyl transferase inhibitor (0.954) |
|
| Not studied | – | Neurodegenerative diseases treatment (0.920) |
|
| Not studied | – | Acaricide (0.721) |
|
| Not studied | – | Not predicted: MolCharge: 1 |
|
| Not studied | – | Not predicted: MolCharge: 1 |
|
| Not studied | – | Antiinfertility, female (0.940) |
|
| Toxic carcinogenic mutagenic neurotoxic | Carcinogenic (0.975) | Embryotoxic (0.957) |
|
| Toxic carcinogenic mutagenic neurotoxic | Carcinogenic (0.975) | Embryotoxic (0.957) |
|
| Not studied | – | Antineoplastic (0.892) |
|
| Toxic carcinogenic mutagenic neurotoxic | Carcinogenic (0.964) | Embryotoxic (0.960) |
|
| Not studied | – | Genital warts treatment (0.876) |
|
| Not studied | – | Antineoplastic (0.892) |
|
| Not studied | – | Antineoplastic (0.892) |
|
| Not studied | – | Antineoplastic (0.897) |
|
| Not studied | – | Antineoplastic (0.889) |
|
| Not studied | – | Antineoplastic (0.889) |
|
| Not studied | – | Antineoplastic (0.900) |
|
| Not studied | – | Antineoplastic (0.889) |
|
| Not studied | – | Antineoplastic (0.889) |
aOnly activities with Pa > 0.5 are shown
Fig. 5Novel biological active azo compounds derived from plants
Fig. 6Bioactive azoxy-glycosides derived from Cycadaceae plants and pyridine derivatives produced by marine sponge
Confirmed and new biological activities of azo compounds (118–125) derived from marine sponge
| No. | Activity reviewed | Activities confirmed (Pa) | Additional predicted activities (Paa) |
|---|---|---|---|
|
| Cytotoxic | Antineoplastic (0.776) | Antieczematic (0.693) |
|
| Cytotoxic | Antineoplastic (0.747) | Cardiovascular analeptic (0.567) |
|
| Cytotoxic | Antineoplastic (0.747) | Cardiovascular analeptic (0.567) |
|
| Cytotoxic | Antineoplastic (0.771) | Antieczematic (0.671) |
|
| Cytotoxic | Antineoplastic (0.771) | Antieczematic (0.671) |
|
| Cytotoxic | Antineoplastic (0.771) | Antieczematic (0.671) |
|
| Cytotoxic | Antineoplastic (0.771) | Antieczematic (0.671) |
|
| Cytotoxic | Antineoplastic (0.776) | Antieczematic (0.693) |
aOnly activities with Pa > 0.5 are shown